FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394517> ?p ?o ?g. }

• W4308394517 abstract "<h3>Background</h3> Immune cell-based therapies, such as bispecific T cell engagers (BiTE), have been developed for treatment of malignancies. However, the current overall success rate of anti-tumor drugs during clinical development remains low. One prominent reason is that the existing animal models in preclinical studies often do not accurately predict the clinical outcomes. The differences between human and mouse immune systems hamper the development of new cancer therapeutic approaches. Herein, we developed a novel humanized mouse model with solid tumor that can allow long-term evaluation of the effectiveness and risk of unwanted toxicity for bispecific immune drugs. <h3>Methods</h3> We utilized two human cancer cell lines in this study: 1) Breast cancer cell MDA-MB-231 (MDA, expressed EGFR); 2) B cell lymphoma Raji (Raji, expressed CD19). To establish the breast tumor model, MDA cells were implanted in NSG-MHC class I/II double knock-out (DKO) mouse via mammary fat pad (MFP) 2 days before humanized mice with human peripheral blood mononuclear cells (PBMCs). The same MDA cells were then intravenously (IV) implanted 3 days before EGFRxCD3 BiTE administration. Similarly, subcutaneous (SC) solid lymphoma model was established and treated with CD19xCD3 BiTE. Following BiTE dosing tumor burden was quantified by a Xenogen imaging system. To evaluate the toxicity levels in response to BiTE therapy, serum inflammatory cytokine levels were analyzed. Clinical observation, mouse clinical score, and body weight change were also monitored for drug toxicity assessment. <h3>Results</h3> PBMC-humanized model with solid tumors were successfully established. Either MFP MDA tumor or SC B cell lymphoma could keep growing for more than one month in the mice. Low dose BiTE treatment did suppress tumor cell growth in the mouse lungs but did not inhibited solid tumor growth. Increased dosage significantly inhibited MFP or SC solid tumor growth. The mice with BiTE treatment exhibited elevated serum levels of human inflammatory cytokines. This cytokine production was dose-dependent and was associated with an increase of toxicity. <h3>Conclusions</h3> This model provides a growth environment like that of the patients with solid tumor and can be used for both short-term and long-term data analysis of efficacy, toxicity, and dosing requirements of immunotherapy drugs. We emphasize that the solid tumor model using both IV and SC/MFP co-engraftment is a promising preclinical platform for simultaneously evaluating long-term efficacy and predictive safety of any T cell-based immunotherapies to define optimal approaches for clinical treatment." @default.
• W4308394517 created "2022-11-11" @default.
• W4308394517 creator A5006856205 @default.
• W4308394517 creator A5029902551 @default.
• W4308394517 creator A5036394378 @default.
• W4308394517 creator A5045307657 @default.
• W4308394517 creator A5059356044 @default.
• W4308394517 creator A5075210236 @default.
• W4308394517 creator A5079343876 @default.
• W4308394517 date "2022-11-01" @default.
• W4308394517 modified "2023-10-16" @default.
• W4308394517 title "1250 A novel in vivo PBMC humanized mouse platform for long-term analysis of efficacy and toxicity of T cell-based immunotherapy drugs" @default.
• W4308394517 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1250" @default.
• W4308394517 hasPublicationYear "2022" @default.
• W4308394517 type Work @default.
• W4308394517 citedByCount "0" @default.
• W4308394517 crossrefType "proceedings-article" @default.
• W4308394517 hasAuthorship W4308394517A5006856205 @default.
• W4308394517 hasAuthorship W4308394517A5029902551 @default.
• W4308394517 hasAuthorship W4308394517A5036394378 @default.
• W4308394517 hasAuthorship W4308394517A5045307657 @default.
• W4308394517 hasAuthorship W4308394517A5059356044 @default.
• W4308394517 hasAuthorship W4308394517A5075210236 @default.
• W4308394517 hasAuthorship W4308394517A5079343876 @default.
• W4308394517 hasBestOaLocation W43083945171 @default.
• W4308394517 hasConcept C121608353 @default.
• W4308394517 hasConcept C126322002 @default.
• W4308394517 hasConcept C137061746 @default.
• W4308394517 hasConcept C202751555 @default.
• W4308394517 hasConcept C203014093 @default.
• W4308394517 hasConcept C2776090121 @default.
• W4308394517 hasConcept C2776156784 @default.
• W4308394517 hasConcept C2777701055 @default.
• W4308394517 hasConcept C2779338263 @default.
• W4308394517 hasConcept C29730261 @default.
• W4308394517 hasConcept C502942594 @default.
• W4308394517 hasConcept C55493867 @default.
• W4308394517 hasConcept C71924100 @default.
• W4308394517 hasConcept C86803240 @default.
• W4308394517 hasConcept C8891405 @default.
• W4308394517 hasConcept C98274493 @default.
• W4308394517 hasConceptScore W4308394517C121608353 @default.
• W4308394517 hasConceptScore W4308394517C126322002 @default.
• W4308394517 hasConceptScore W4308394517C137061746 @default.
• W4308394517 hasConceptScore W4308394517C202751555 @default.
• W4308394517 hasConceptScore W4308394517C203014093 @default.
• W4308394517 hasConceptScore W4308394517C2776090121 @default.
• W4308394517 hasConceptScore W4308394517C2776156784 @default.
• W4308394517 hasConceptScore W4308394517C2777701055 @default.
• W4308394517 hasConceptScore W4308394517C2779338263 @default.
• W4308394517 hasConceptScore W4308394517C29730261 @default.
• W4308394517 hasConceptScore W4308394517C502942594 @default.
• W4308394517 hasConceptScore W4308394517C55493867 @default.
• W4308394517 hasConceptScore W4308394517C71924100 @default.
• W4308394517 hasConceptScore W4308394517C86803240 @default.
• W4308394517 hasConceptScore W4308394517C8891405 @default.
• W4308394517 hasConceptScore W4308394517C98274493 @default.
• W4308394517 hasLocation W43083945171 @default.
• W4308394517 hasOpenAccess W4308394517 @default.
• W4308394517 hasPrimaryLocation W43083945171 @default.
• W4308394517 hasRelatedWork W1996150995 @default.
• W4308394517 hasRelatedWork W2023771859 @default.
• W4308394517 hasRelatedWork W2380021556 @default.
• W4308394517 hasRelatedWork W2381196212 @default.
• W4308394517 hasRelatedWork W2464386733 @default.
• W4308394517 hasRelatedWork W2763883091 @default.
• W4308394517 hasRelatedWork W2901646808 @default.
• W4308394517 hasRelatedWork W3180780036 @default.
• W4308394517 hasRelatedWork W4291367166 @default.
• W4308394517 hasRelatedWork W4360983034 @default.
• W4308394517 isParatext "false" @default.
• W4308394517 isRetracted "false" @default.
• W4308394517 workType "article" @default.